Active substances
Mifepristone + Misoprostol
- Health Canada 2
- UK MHRA 1
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| FEMYSO | 02560569 | 200 MCG; 200 MG | TABLET; KIT · ORAL; BUCCAL | LUPIN PHARMA CANADA LIMITED |
| MIFEGYMISO | 02444038 | 200 MCG; 200 MG | KIT; TABLET · BUCCAL; ORAL | LINEPHARMA INTERNATIONAL LIMITED |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| MEDABON: COMBIPACK OF MIFEPRISTONE 200 MG TABLET AND MISOPROSTOL 4 X 0.2 MG VAGINAL TABLETS | PL 31750/0042 | SUN PHARMACEUTICAL INDUSTRIES EUROPE BV | POM |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.